脑出血中的预防性抗惊厥药
该研究在两家学术中心回顾性纳入610例原发性脑出血患者,其中98例启动预防性抗惊厥药,左乙拉西坦占97%。年龄、脑叶出血、较高初始NIHSS评分、开颅手术及既往脑出血史与预防性用药独立相关。经倾向匹配后,预防性抗惊厥药与出院时改良Rankin评分4-6分或病死率增加无关。2010年指南发布后处方模式无差异。
要点
- 610例原发性脑出血患者中98例(左乙拉西坦占97%)启动预防性抗惊厥药。
- 年龄(OR 0.97,95%CI 0.95-0.99,p<.001)与预防性抗惊厥药启动独立相关。
- 脑叶出血(OR 2.94,95%CI 1.76-4.91,p<.001)与预防性抗惊厥药启动独立相关。
- 较高初始NIHSS评分(OR 2.31,95%CI 1.40-3.79,p=.001)、开颅手术(OR 3.06,95%CI 1.51-6.20,p=.002)、既往脑出血(OR 2.36,95%CI 1.10-5.07,p=.028)与预防性抗惊厥药启动独立相关。
- 预防性抗惊厥药与出院时mRS 4-6分或病死率增加无关;2010年指南发布后处方模式无差异。
适用人群与场景
- 两家学术中心收治的原发性脑出血患者。
研究设计与关键结果
- 回顾性研究纳入610例原发性脑出血患者,其中98例启动预防性抗惊厥药,左乙拉西坦占97%。
- 年龄(OR 0.97,95%CI 0.95-0.99,p<.001)、脑叶出血(OR 2.94,95%CI 1.76-4.91,p<.001)、较高初始NIHSS评分(OR 2.31,95%CI 1.40-3.79,p=.001)、开颅手术(OR 3.06,95%CI 1.51-6.20,p=.002)、既往脑出血(OR 2.36,95%CI 1.10-5.07,p=.028)与预防性抗惊厥药启动独立相关。
- 预防性抗惊厥药使用与出院时改良Rankin评分4-6分或病死率增加无关。
- 2010年指南发布后处方模式无差异。
证据类型、等级与局限
- 证据类型:回顾性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为未来研究应考察预防性左乙拉西坦对费用和神经心理学结局的影响,以及连续脑电图在识别亚临床发作中的作用。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: Prophylactic anticonvulsants are routinely prescribed in the acute setting for intracerebral hemorrhage (ICH) patients, but some studies have reported an association with worse outcomes. We sought to characterize the prevalence and predictors of prophylactic anticonvulsant administration after ICH as well as guideline adherence. We also sought to determine whether prophylactic anticonvulsants were independently associated with poor outcome.
METHODS: We performed a retrospective study of primary ICH in our two academic centers. We used a propensity matching approach to make treated and non-treated groups comparable. We conducted multiple logistic regression analysis to identify independent predictors of prophylactic anticonvulsant initiation and its association with poor outcome as measured by modified Rankin score.
RESULTS: We identified 610 patients with primary ICH, of whom 98 were started on prophylactic anticonvulsants. Levetiracetam (97%) was most commonly prescribed. Age (OR 0.97, 95% CI 0.95-0.99, p < .001), lobar location (OR 2.94, 95% CI 1.76-4.91, p < .001), higher initial National Institutes of Health Stroke Scale (NIHSS) score (OR 2.31, 95% CI 1.40-3.79, p = .001), craniotomy (OR 3.06, 95% CI 1.51-6.20, p = .002), and prior ICH (OR 2.36, 95% CI 1.10-5.07, p = .028) were independently associated with prophylactic anticonvulsant initiation. Prophylactic anticonvulsant use was not associated with worse functional outcome [modified Rankin score (mRS) 4-6] at hospital discharge or with increased case-fatality. There was no difference in prescribing patterns after 2010 guideline publication.
DISCUSSION: Levetiracetam was routinely prescribed following ICH and was not associated with worse outcomes. Future investigations should examine the effect of prophylactic levetiracetam on cost and neuropsychological outcomes as well as the role of continuous EEG in identifying subclinical seizures.
参考来源
- Mackey J, Blatsioris AD, Moser EAS, et al. Prophylactic Anticonvulsants in Intracerebral Hemorrhage. Neurocrit Care. 2017. PMID: 28324261. doi:10.1007/s12028-017-0385-8
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。